practice. All HTA bodies recommended the three biologic therapies for use in patients with moderate to severe plaque psoriasis who have failed to respond to standard systemic therapies with discontinuation rules if no response was observed after 12-16 (16-20: ixekizumab (SMC)) weeks. Conclusions: The evidence base, and HTA agency decisions, for guselkumab, ixekizumab, and brodalumab submissions were principally aligned. As more biologics are being approved, understanding the requirements of HTA, and undertaking holistic evidence generation, will play a crucial role in enabling access to the novel biologics.